Oneness Biotech, founded in June 2008, is a biopharmaceutical company operating in the field of innovative drugs. On September 23, 2011, the company was officially listed on the Taiwan Stock Exchange under the symbol 4743. In 2020, Oneness Biotech has once received the recognition in the MSCI Global Standard Index. The company's mission is "Developing new drugs, Caring for life."

Developing New Drugs, Caring for Life

Oneness is dedicated to the research and development of globally innovative pharmaceuticals. The research team is committed to addressing unmet medical needs, striving to guide patients out of the depths of illness and bring about transformative changes in their lives. Focusing on the treatment of chronic skin and immune diseases, Oneness possesses a comprehensive portfolio of new drug development. Among them, after 15 years of research, we have successfully developed the world's first breakthrough new drug, "FESPIXON^®" cream, specifically designed for patients with diabetic foot ulcers.

Changing the Lives of 200 Million Potential Diabetic Foot Ulcer Patients Worldwide – FESPIXON^®

The global diabetic population is estimated to exceed 640 million by 2030, with one in every three diabetes patients at risk of developing foot ulcers in their lifetime. Without early detection or proper care, ulcers may lead to infections, gangrene, and even amputation. According to statistics, patients who undergo amputation face a staggering 70% risk of death within five years. Diabetic foot ulcers are a severe and life-threatening complication.

Previously, there were no effective medications for the complete healing of Diabetic Foot Ulcers (DFU). Oneness innovatively developed the new drug "FESPIXON^®" cream, employing a novel mechanism to regulate macrophages, achieve wound environment balance, and thereby promote effective tissue repair to treat diabetic foot ulcers. The results of international multicenter phase III clinical trial, along with the innovative drug mechanism, were published in the prestigious medical journal JAMA Network Open in September 2021 and JID Innovations in June 2022.

Clinical trial results show that "FESPIXON^®" cream completely heals nearly twice of the proportion of DFU patients compared to conventional dressing for diabetic foot ulcers. The results are statistically significant, confirming that the wounds were healed rapidly and completely. This outcome represents a revolutionary impact on the care of diabetic foot ulcers.

Caring for the Social Environment, Connecting Love

Starting from the core business of new drug development, we collaborate with major medical associations to disseminate accurate health education knowledge to the general public. Moreover, through partnerships with renowned medical centers in Taiwan, we donate "FESPIXON^®" cream to support the care for global diabetic foot ulcer patients.

Caring for the Vulnerable, Empowering Life Changes

Diabetic foot ulcers rank among the top 10 diseases globally in medical expenditure, with approximately 20-30% of patients eventually facing amputation. The mortality rate after amputation is comparable to that of cancer diseases. Oneness aims to assist patients who cannot afford medical expenses, providing them with an opportunity for life-changing experiences. Currently, a subsidy program for low-income households has been established in Taiwan, with attmpts of helping more patient groups receive early treatment, avoiding amputation, and maintaining a good quality of life while saving lives.

Collaborating with Hospital Partners, Sending Love to Overseas Patients

In 2023, Oneness collaborates with Taiwan's Shuang Ho Hospital to jointly donate "FESPIXON^®" cream to the Marshall Islands. Additionally, we join forces with the plastic surgery medical volunteer team from Shin Kong Wu Ho Su Memorial Hospital to assist diabetic foot patients in Palau.

Pursuing Innovation, Developing Resilience

Oneness understands the prolonged and agonizing wait faced by patients without appropriate medications. Therefore, we persistently invest significant resources and time in the research and development of botanical drugs, small-molecule drugs, and antibody drugs. Guided by the mission of caring for life, we continually strive to create new milestones in science. By enhancing collaboration with international pharmaceutical companies, we aspire to accompany patients worldwide out of the shadows on their journey of life, and bring the dawn of healing to transform lives.

Global Awards

• 2010: National Quality Mark Certificate
• 2014: National Biotech Medical Quality Bronze Award (Nutritional Health Food Category, Health Food Group)
• 2016: Ministry of Health and Welfare, Ministry of Economic Affairs Award for Drug Technology Research and Development, Bronze Award in the Pharmaceutical Category
• 2016: 13th National Innovation Award, Corporate Innovation Award in the Biopharmaceutical and New Medical Technology Category
• 2022: Asia Business Association "International Innovation Award"
• 2023: Selected for S&P Global's "2023 Sustainability Yearbook" and awarded the "Best Progress Award" in international sustainability assessments.